Search by Drug Name or NDC

    NDC 68180-0286-07 ABACAVIR, LAMIVUDINE AND ZIDOVUDINE 300; 150; 300 mg/1; mg/1; mg/1 Details

    ABACAVIR, LAMIVUDINE AND ZIDOVUDINE 300; 150; 300 mg/1; mg/1; mg/1

    ABACAVIR, LAMIVUDINE AND ZIDOVUDINE is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Lupin Pharmaceuticals, Inc.. The primary component is ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE.

    Product Information

    NDC 68180-0286
    Product ID 68180-286_e180b9ff-1e7c-422a-9fe7-afd39eee3e4e
    Associated GPIs 12109903200320
    GCN Sequence Number 047121
    GCN Sequence Number Description abacavir/lamivudine/zidovudine TABLET 150-300 MG ORAL
    HIC3 W5L
    HIC3 Description ANTIVIRALS, HIV-SPEC., NUCLEOSIDE ANALOG, RTI COMB
    GCN 87691
    HICL Sequence Number 021800
    HICL Sequence Number Description ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE
    Brand/Generic Generic
    Proprietary Name ABACAVIR, LAMIVUDINE AND ZIDOVUDINE
    Proprietary Name Suffix n/a
    Non-Proprietary Name ABACAVIR , LAMIVUDINE AND ZIDOVUDINE
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET
    Route ORAL
    Active Ingredient Strength 300; 150; 300
    Active Ingredient Units mg/1; mg/1; mg/1
    Substance Name ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
    Labeler Name Lupin Pharmaceuticals, Inc.
    Pharmaceutical Class Cytochrome P450 1A1 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse T
    DEA Schedule n/a
    Marketing Category ANDA
    Application Number ANDA202912
    Listing Certified Through 2024-12-31

    Package

    NDC 68180-0286-07 (68180028607)

    NDC Package Code 68180-286-07
    Billing NDC 68180028607
    Package 1 BOTTLE in 1 CARTON (68180-286-07) / 60 TABLET in 1 BOTTLE
    Marketing Start Date 2013-12-17
    NDC Exclude Flag N
    Pricing Information N/A